TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In an October 6, 2026, first-person report for Being Patient, Ron Carr recounts three health notifications that altered how he thinks about Alzheimer’s risk. The supplied excerpt details an APOE4 result and a coronary artery calcium scan showing plaque; it does not include the third notification or the full report, and neither account establishes that Carr has Alzheimer’s disease.
Ron Carr, a retired local government executive and patient advocate, says two health notifications changed how he thinks about Alzheimer’s risk: a genetic test showing two copies of APOE4 and a coronary scan showing calcified plaque. In a first-person report published by Being Patient on October 6, 2026, Carr describes how the results prompted him to learn about risk and discuss prevention with his clinicians; the excerpt supplied for this article does not describe the third notification named in the headline.
Carr writes that he learned of his APOE4 status about two years earlier. He initially experienced the result as a prediction of his future and began treating ordinary lapses, such as forgetting a name or misplacing keys, as possible warning signs. He then immersed himself in Alzheimer’s research and repeatedly changed his diet, exercise routine and supplement use. He also says he took prescription sleeping pills that left him groggy and irritable.
Over time, Carr came to understand the result as a risk factor, not an Alzheimer’s diagnosis, a distinction also discussed in research on genes and APOE4 Alzheimer’s risk. He says learning more about the distinction helped him feel less helpless and focus on risks he believed could be addressed. The essay cites a Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That estimate concerns dementia at a population level; it does not establish what caused, or will cause, cognitive changes in Carr or any individual.
The second notification followed a coronary artery calcium scan, which Carr says his USC clinician recommended in light of his APOE4 status. Although he felt healthy and had cholesterol levels his physician considered acceptable, the scan showed significant calcified plaque, concentrated largely in his left anterior descending artery. Carr says his clinicians then lowered his LDL cholesterol and ApoB targets and changed his treatment plan. He reports that follow-up testing showed no evidence of structural heart damage.
How the Scan Changed His Prevention Plan
Carr’s account illustrates how a risk result and a separate imaging finding can lead to different kinds of clinical conversations. He describes the genetic result as information about increased risk rather than a diagnosis; the scan, by contrast, identified calcified plaque in his coronary arteries. In his case, the latter prompted his clinicians to revise his cardiovascular prevention plan.
The distinction matters to readers because genetic information can feel like a fixed forecast, while a risk marker is not the same as certainty about an individual outcome. Carr says his early response included anxiety and frequent changes to diet, exercise and supplements. His later perspective was more measured: he says he focused on discussions with clinicians and on factors he could address. His personal experience does not show that a particular diet, supplement or test prevents Alzheimer’s disease.
The essay also links brain-health concerns with cardiovascular health through Carr’s own experience. It reports that his clinician considered his APOE4 status relevant to lipid transport and arranged a heart scan. The account underscores why an individual’s test results and treatment decisions need clinical interpretation, rather than conclusions based on a single gene or a general risk estimate.
As an affiliate, we earn on qualifying purchases.
From Family Heart History to Testing
Carr says his father had a heart attack at age 65 and survived, but his life became more limited afterward. Carr writes that this family experience influenced his own efforts to protect his heart. He ran long distances, adopted what he considered a heart-healthy diet and eventually accepted statin therapy after initially resisting it.
The scan came after Carr had believed his cholesterol was at acceptable levels. He describes its result as a surprise because he had no symptoms and expected reassurance. He contrasts his father’s first indication of heart disease—a heart attack—with his own finding through imaging. The essay presents that contrast as a personal account of how testing affected his decisions, not as evidence that screening is appropriate for everyone.
Being Patient identifies Carr as an advocate focused on Alzheimer’s prevention, genetic testing and cardiovascular health. He says he has shared his perspective through the USC Center for Personalized Brain Health and the Family Heart Foundation, where he serves as an ambassador. These affiliations provide context for his essay; they do not independently verify the clinical details he recounts.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, in Being Patient
The Third Notification Is Missing
The source material provided here ends during Carr’s account of his second notification. Although the headline refers to three health notifications, it does not include the third result or how Carr says it affected him. That part of the report cannot be summarized or verified from the supplied excerpt.
The excerpt also does not provide the scan’s numerical calcium score, dates of the imaging and follow-up tests, or the specific medication doses and treatment targets. It gives no independent medical records or clinician comments. Carr’s narrative should therefore be read as his account of his care, not as a complete clinical record or general screening guidance.
Nothing in the supplied material says Carr has Alzheimer’s disease. His APOE4 result indicates genetic risk, as he explains, while the reported scan finding concerns his heart. The excerpt does not establish whether Carr has experienced cognitive impairment or what his individual future risk may be.
Further Details Depend on the Full Report
The next step for readers seeking the complete account is to consult the full Being Patient report, which may describe Carr’s third notification and the conversations that followed. The supplied material gives no date or specific milestone for further testing or an additional clinical update.
Carr’s essay describes changes made with clinician involvement, including adjustments to cardiovascular treatment after the scan. It does not set out a universal plan for people with APOE4 or recommend that every reader receive genetic testing or coronary imaging. Anyone weighing personal test results or treatment decisions should discuss them with a qualified health professional who can consider their medical history and circumstances.
Key Questions
What did Carr learn from his genetic test?
He writes that the test showed he carries two copies of APOE4, a genetic risk factor associated with late-onset Alzheimer’s disease. The result is not an Alzheimer’s diagnosis.
What did the heart scan show?
Carr says a coronary artery calcium scan found significant calcified plaque, concentrated largely in his left anterior descending artery. He reports that follow-up testing showed no structural heart damage.
Does APOE4 mean someone will develop Alzheimer’s?
No. Carr’s essay describes APOE4 as a risk factor, not a diagnosis. The excerpt does not give an individual probability for Carr or establish that he has Alzheimer’s disease.
What was Carr’s third health notification?
The supplied excerpt does not say. It ends while Carr is discussing the second notification, so the third result and its consequences remain unclear from the available material.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
